Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from TD Cowen

Key Points

• TD Cowen raised Regeneron’s price target from $960 to $980 and maintained a “buy” rating, implying 21.76% upside from the reported $804.88 share price.
• Analyst sentiment remains favorable overall, with a consensus rating of “Moderate Buy” and an average price target of $846.28, despite several firms maintaining neutral or hold ratings.
• Regeneron reported strong quarterly results, earning $14.29 per share versus the $10.16 consensus estimate and generating $4.29 billion in revenue, up 16.7% year over year.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective hoisted by analysts at TD Cowen from $960.00 to $980.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. TD Cowen's price target points to a potential upside of 21.76% from the company's current price.

A number of other research analysts also recently weighed in on the stock. Sanford C. Bernstein raised their price target on shares of Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the company a "market perform" rating in a report on Friday, August 14th. Weiss Ratings reiterated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. Morgan Stanley increased their target price on shares of Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 7th. Robert W. Baird raised their target price on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the company a "neutral" rating in a report on Friday, July 31st. Finally, Wells Fargo & Company boosted their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $846.28.

Regeneron Pharmaceuticals Stock Down 0.3%

Shares of Regeneron Pharmaceuticals stock traded down $2.60 during trading on Wednesday, hitting $804.88. 202,661 shares of the stock traded hands, compared to its average volume of 815,764. The stock has a market cap of $82.87 billion, a P/E ratio of 19.87, a PEG ratio of 1.35 and a beta of 0.16. The company has a fifty day moving average price of $791.41 and a two-hundred day moving average price of $721.87. Regeneron Pharmaceuticals has a twelve month low of $572.75 and a twelve month high of $859.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company's revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company earned $12.81 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals will post 47.98 EPS for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, insider Andrew Murphy sold 4,147 shares of the stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the completion of the transaction, the insider directly owned 47,833 shares in the company, valued at $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the business's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Large investors have recently bought and sold shares of the business. SHP Wealth Management acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $26,000. Western Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the first quarter worth $26,000. Armstrong Advisory Group Inc. raised its stake in Regeneron Pharmaceuticals by 466.7% during the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 28 shares during the last quarter. Trust Co. of Vermont acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at $29,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.